In Veritas Medical Stock Total Debt
| IVME Stock | USD 0.0001 0.00 0.00% |
In Veritas Medical fundamentals help investors to digest information that contributes to In Veritas' financial success or failures. It also enables traders to predict the movement of IVME Stock. The fundamental analysis module provides a way to measure In Veritas' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to In Veritas stock.
As of November 30, 2024, Total Debt To Capitalization is expected to decline to -1.04. IVME | Total Debt |
In Veritas Medical Company Total Debt Analysis
In Veritas' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current In Veritas Total Debt | 1.21 M |
Most of In Veritas' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, In Veritas Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IVME Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for In Veritas is extremely important. It helps to project a fair market value of IVME Stock properly, considering its historical fundamentals such as Total Debt. Since In Veritas' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of In Veritas' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of In Veritas' interrelated accounts and indicators.
Click cells to compare fundamentals
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
IVME Long Term Debt
Long Term Debt |
|
Based on the latest financial disclosure, In Veritas Medical has a Total Debt of 1.21 M. This is 100.0% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The total debt for all United States stocks is 99.98% higher than that of the company.
IVME Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses In Veritas' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of In Veritas could also be used in its relative valuation, which is a method of valuing In Veritas by comparing valuation metrics of similar companies.In Veritas is currently under evaluation in total debt category among its peers.
IVME Fundamentals
| Return On Asset | -6.48 | ||||
| Current Valuation | 8.6 K | ||||
| Shares Outstanding | 86.05 M | ||||
| Price To Earning | (0.01) X | ||||
| Price To Sales | 0.14 X | ||||
| EBITDA | (2.07 M) | ||||
| Net Income | (3.67 M) | ||||
| Total Debt | 1.21 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (727.72 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | 9.03 | ||||
| Market Capitalization | 8.61 K | ||||
| Total Asset | 111.95 K | ||||
| Net Asset | 111.95 K |
About In Veritas Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze In Veritas Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of In Veritas using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of In Veritas Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether In Veritas Medical is a strong investment it is important to analyze In Veritas' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact In Veritas' future performance. For an informed investment choice regarding IVME Stock, refer to the following important reports:Check out In Veritas Piotroski F Score and In Veritas Altman Z Score analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In Veritas. If investors know IVME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In Veritas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (6.48) |
The market value of In Veritas Medical is measured differently than its book value, which is the value of IVME that is recorded on the company's balance sheet. Investors also form their own opinion of In Veritas' value that differs from its market value or its book value, called intrinsic value, which is In Veritas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In Veritas' market value can be influenced by many factors that don't directly affect In Veritas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In Veritas' value and its price as these two are different measures arrived at by different means. Investors typically determine if In Veritas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In Veritas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.